Clinical Trials Logo

Recurrent WHO Grade III Glioma clinical trials

View clinical trials related to Recurrent WHO Grade III Glioma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04044937 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms

UC-GlioFET
Start date: October 29, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back. FET accumulates in malignant cells within intracranial neoplasms and can be used to detect recurrent disease and characterize the grade of glial neoplasms. Imaging agents such as FET can help oncologist to see the tumor better during a positron emission tomography (PET) scan.

NCT ID: NCT02208362 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Start date: May 18, 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory). A T cell is a type of immune cell that can recognize and kill abnormal cells in the body. T cells are taken from the patient's blood and a modified gene is placed into them in the laboratory and this may help them recognize and kill glioma cells. Genetically modified T-cells may also help the body build an immune response against the tumor cells.

NCT ID: NCT02192359 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Start date: March 7, 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of carboxylesterase-expressing allogeneic neural stem cells when given together with irinotecan hydrochloride in treating patients with high-grade gliomas that have come back. Placing genetically modified neural stem cells into brain tumor cells may make the tumor more sensitive to irinotecan hydrochloride. Irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving carboxylesterase-expressing allogeneic neural stem cells and irinotecan hydrochloride may be a better treatment for high-grade gliomas.